Synlogic (SYBX) Registration Filing summary

Company overview and business model

• Focuses on developing novel therapeutics for rare metabolic disorders, leveraging engineered probiotics to create GI-restricted oral medicines targeting specific biological pathways.

• Lead programs included labafenogene marselecobac (SYNB1934) for phenylketonuria (PKU) and SYNB1353 for homocystinuria (HCU), with additional early-stage candidates for enteric hyperoxaluria, gout, and cystinuria.

• Discontinued pivotal Phase 3 study for SYNB1934 in February 2024 after internal review indicated the trial was unlikely to meet its primary endpoint; no safety concerns were cited.

• Current strategy centers on pursuing strategic alternatives, including a merger or sale, to enhance stockholder value.

• Pipeline is based on a proprietary platform using Escherichia coli Nissle 1917, enabling synergies and leveraging established manufacturing processes.

Use of proceeds and capital allocation

• Net proceeds from securities sales are intended for general corporate purposes, including R&D, working capital, capital expenditures, investments, acquisitions, and collaborations.

• Management retains broad discretion over allocation and timing of expenditures; proceeds may be temporarily invested in short-term, investment-grade securities or used to reduce short-term debt.

Risk factors and disclosures

• Investment involves significant risk, with detailed risk factors to be provided in prospectus supplements and incorporated SEC filings.

• Risks include uncertainties in clinical development, regulatory approval, strategic transaction outcomes, and market competition.

• Forward-looking statements are subject to known and unknown risks that may cause actual results to differ materially.